X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Lead Product(s): Pindolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mankind Pharma
Deal Size: $12.1 million Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2023
Details:
S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Lead Product(s): Pindolol
Therapeutic Area: Musculoskeletal Product Name: ACM-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.
Lead Product(s): Pindolol
Therapeutic Area: Oncology Product Name: ACM-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
